Immunotherapy plus radiation after surgery for upper tract cancer
Part of Cancer clinical trials.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with high-risk upper urinary tract urothelial cancer (a type of cancer in the kidney or ureter).
- You are at least 18 years old.
- Your cancer was high-risk, meaning it had certain features like being stage pT2 or higher, or had spread to lymph nodes.
- You had surgery to remove all visible cancer (R0 resection) and no distant spread was found.
- You haven't had radiation or chemotherapy to your pelvis or abdomen before.
- You are not pregnant, and if you could become pregnant, you agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.